Results 21 to 30 of about 2,387 (195)

Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network [PDF]

Human Vaccines & Immunotherapeutics
Although clinical trials have shown that nirsevimab is safe, post-licensure safety data from routine clinical settings are lacking. This study describes parent-reported health events occurring within seven days of nirsevimab administration.
Marina Viñeta Paramo, Marilou Kiely, Louis Valiquette, Matthew P. Muller, Allison McGeer, Jennifer E. Isenor, Manish Sadarangani, James D. Kellner, Otto G. Vanderkooi, Kimberly Marty, Pascal M. Lavoie, Julie A. Bettinger   +11 more
doaj   +2 more sources

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants [PDF]

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +2 more sources

Coverage, Timing, Safety, and Determinants of Neonatal Intensive Care Unit Admission in Newborns Receiving Nirsevimab Prophylaxis for Respiratory Syncytial Virus [PDF]

Pathogens
Background: Nirsevimab, a long-acting monoclonal antibody targeting respiratory syncytial virus (RSV), has recently been introduced as universal prophylaxis in newborns and infants. Although clinical trials have shown high efficacy and a favorable safety
Maria Costantino, Valentina Giudice, Anna Maria Della Corte, Silvia Pecoraro, Anna Rita Frascogna, Giuseppe Marchesano, Sabino Moschella, Carmela Alfano, Federica Santaniello, Carmine Brengola, Giuseppina Napoletano, Virginia Caputo, Antonio Luciano, Assunta Santullo, Luca Pierri, Federica Aiello, Maria Carmen De Caro, Luciana Catena, Concetta Sarnataro, Francesco De Caro, Maria Grazia Corbo   +20 more
doaj   +2 more sources

Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis

Pediatric Reports
Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy ...
Brody J. Lipsett, Benjamin N. Fogel, Katherine E. Shedlock, Ian M. Paul, Eric W. Schaefer, Ruth E. Gardner, Leah D. Kaye, Steven D. Hicks   +7 more
doaj   +2 more sources

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States [PDF]

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal ...
Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha   +7 more
doaj   +2 more sources

Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study [PDF]

Infectious Diseases and Therapy
Introduction Germany’s Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect ...
Caroline Lade, Erin Quinn, Lea J. Bayer, Amy W. Law, Christof von Eiff, Julia Schiffner-Rohe, Mark Atwood, Bennet Huebbe, Ahuva Averin   +8 more
doaj   +2 more sources

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis [PDF]

Frontiers in Pediatrics
ObjectiveRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications.
Shunli Liu, Shunli Liu, Yan Wang, Yan Wang, Yang Cao, Yang Cao, Huiling Song, Huiling Song, Zhiqing Tian, Zhiqing Tian, Xue Li, Xue Li, Lan Huang, Lan Huang   +13 more
doaj   +2 more sources

Potential Effects on Elderly People From Nirsevimab Use in Infants

Open Respiratory Archives
Nirsevimab therapy has the potential to revolutionize infant respiratory syncytial virus (RSV) prophylaxis. But other populations suffering RSV, such the elderly or those over 60, may also be protected by using this novel antibody in the infant group. It
José María Eiros Bouza, Iván Sanz Muñoz, Javier Castrodeza-Sanz   +2 more
exaly   +3 more sources

RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience. [PDF]

Health Sci Rep
ABSTRACT Background New respiratory syncytial virus (RSV) preventative programs are launching globally. Our Australian jurisdiction implemented RSV monoclonal antibody provision via pediatric and perinatal hospitals for highest risk neonates and infants.
Tuckerman J, Cheng DR, Hunter G, Elia S, Hearn T, Verma D, Jacobs S, Carr J, Crawford NW.   +8 more
europepmc   +2 more sources

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier   +14 more
doaj   +2 more sources